{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Traditional Chinese Medicine", "diabetes", "gut microbiota", "literature review", "obesity"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37600709", "DateCompleted": {"Year": "2023", "Month": "08", "Day": "24"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "06"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "08", "Day": "01"}], "Language": ["eng"], "ELocationID": ["1218880", "10.3389/fendo.2023.1218880"], "Journal": {"ISSN": "1664-2392", "JournalIssue": {"Volume": "14", "PubDate": {"Year": "2023"}}, "Title": "Frontiers in endocrinology", "ISOAbbreviation": "Front Endocrinol (Lausanne)"}, "ArticleTitle": "Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature.", "Pagination": {"StartPage": "1218880", "MedlinePgn": "1218880"}, "Abstract": {"AbstractText": ["Obesity and diabetes are closely related metabolic disorders that have become major public health concerns worldwide. Over the past few decades, numerous studies have explored the underlying mechanisms of these disorders and identified various risk factors, including genetics, lifestyle, and dietary habits. Traditional Chinese Medicine (TCM) has been increasingly recognized for its potential to manage obesity and diabetes. Weight loss is difficult to sustain, and several diabetic therapies, such as sulfonylureas, thiazolidinediones, and insulin, might make it harder to lose weight. While lifestyle changes should be the primary approach for people interested in lowering weight, drugs are also worth investigating. Since some of the newer glucose-lowering medications that cause weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are additionally utilized or are under consideration for use as anti-obesity drugs, the frontier between glucose-lowering medication and weight loss drugs appears to be shifting. This review provides an overview of the literature on the underlying mechanisms of obesity and diabetes and the prospect of TCM in their management. We discuss the various TCM interventions, including acupuncture, herbal medicine, and dietary therapy, and their effects on metabolic health. We also highlight the potential of TCM in regulating gut microbiota, reducing inflammation, and improving insulin sensitivity. The findings suggest that TCM may provide a promising approach to preventing and managing obesity and diabetes. However, further well-designed studies are needed to confirm the efficacy and safety of TCM interventions and to elucidate their underlying mechanisms of action."], "CopyrightInformation": "Copyright \u00a9 2023 Chen, Liu, Teia and Xie."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China."}, {"Identifier": [], "Affiliation": "Hunan Engineering Technology Research Center for Medicinal and Functional Food, Hunan University of Chinese Medicine, Changsha, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of TCM Heart and Lung Syndrome Differentiation and Medicated Diet and Dietotherapy, Hunan University of Chinese Medicine, Changsha, China."}], "LastName": "Chen", "ForeName": "Yan-Kun", "Initials": "YK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China."}, {"Identifier": [], "Affiliation": "Hunan Engineering Technology Research Center for Medicinal and Functional Food, Hunan University of Chinese Medicine, Changsha, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of TCM Heart and Lung Syndrome Differentiation and Medicated Diet and Dietotherapy, Hunan University of Chinese Medicine, Changsha, China."}], "LastName": "Liu", "ForeName": "Ting-Ting", "Initials": "TT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Agro-technology, Medicinal and Aromatic Plants and Traditional Medicine Research Institute, National Centre for Research, Khartoum, Sudan."}], "LastName": "Teia", "ForeName": "Farah Khameis Farag", "Initials": "FKF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China."}, {"Identifier": [], "Affiliation": "Hunan Engineering Technology Research Center for Medicinal and Functional Food, Hunan University of Chinese Medicine, Changsha, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of TCM Heart and Lung Syndrome Differentiation and Medicated Diet and Dietotherapy, Hunan University of Chinese Medicine, Changsha, China."}], "LastName": "Xie", "ForeName": "Meng-Zhou", "Initials": "MZ"}], "PublicationTypeList": ["Journal Article", "Review", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Endocrinol (Lausanne)", "NlmUniqueID": "101555782", "ISSNLinking": "1664-2392"}, "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapy"], "DescriptorName": "Diabetes Mellitus"}, {"QualifierName": ["therapy"], "DescriptorName": "Obesity"}, {"QualifierName": ["methods"], "DescriptorName": "Medicine, Chinese Traditional"}, {"QualifierName": [], "DescriptorName": "Gastrointestinal Microbiome"}, {"QualifierName": [], "DescriptorName": "Acupuncture"}, {"QualifierName": [], "DescriptorName": "Herbal Medicine"}], "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. . Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2015) 100(2):342\u201362. doi: 10.1210/jc.2014-3415", "ArticleIdList": ["10.1210/jc.2014-3415", "25590212"]}, {"Citation": "World Health Organization Noncommunicable Diseases Country Profiles . WHO Global Report. Geneva: WHO. (2011)."}, {"Citation": "Forse RA, Betancourt-Garcia MM, Kissee MC. Epidemiology and discrimination in obesity. In: The ASMBS textbook of bariatric surgery Springer; (2020). p. 3\u201314."}, {"Citation": "Smith KB, Smith MS. Obesity statistics. Primary care: Clinics office Pract (2016) 43(1):121\u201335. doi: 10.1016/j.pop.2015.10.001", "ArticleIdList": ["10.1016/j.pop.2015.10.001", "26896205"]}, {"Citation": "James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res (2001) 9(S11):228S\u201333S. doi: 10.1038/oby.2001.123", "ArticleIdList": ["10.1038/oby.2001.123", "11707546"]}, {"Citation": "Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. . Multicenter, placebo-controlled trial of lorcaserin for weight management. New Engl J Med (2010) 363(3):245\u201356. doi: 10.1056/NEJMoa0909809", "ArticleIdList": ["10.1056/NEJMoa0909809", "20647200"]}, {"Citation": "Sidhu S, Parikh T, Burman KD. Endocrine Changes in Obesity. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al., editors. Endotext. South Dartmouth (MA): MDText. com, Inc; (2022)."}, {"Citation": "Zhang Y, Yu L, Cai W, Fan S, Feng L, Ji G, et al. . Protopanaxatriol, a novel PPAR\u03b3 antagonist from Panax ginseng, alleviates steatosis in mice. Sci Rep (2014) 4(1):7375. doi: 10.1038/srep07375", "ArticleIdList": ["10.1038/srep07375", "PMC4260220", "25487878"]}, {"Citation": "Miranda J, V\u00e1zquez-Polo M, P\u00e9rez-Junkera G, Fern\u00e1ndez-Gil MDP, Bustamante M\u00c1., Navarro V, et al. . FODMAP intake in Spanish population: open approach for risk assessment. Int J Environ Res Public Health (2020) 17(16):5882. doi: 10.3390/ijerph17165882", "ArticleIdList": ["10.3390/ijerph17165882", "PMC7459496", "32823689"]}, {"Citation": "Pollex RL, Hanley AJ, Zinman B, Harris SB, Khan HM, Hegele RA. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis (2006) 184(1):121\u20139. doi: 10.1016/j.atherosclerosis.2005.03.024", "ArticleIdList": ["10.1016/j.atherosclerosis.2005.03.024", "15869758"]}, {"Citation": "Kumar M, Guleria S, Chawla P, Khan A, Modi VK, Kumar N, et al. . Anti-obesity efficacy of the selected high altitude Himalayan herbs: In vitro studies. J Food Sci Technol (2020) 57:3081\u201390. doi: 10.1007/s13197-020-04341-5", "ArticleIdList": ["10.1007/s13197-020-04341-5", "PMC7316926", "32624610"]}, {"Citation": "Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. Jama (2006) 295(13):1549\u201355. doi: 10.1001/jama.295.13.1549", "ArticleIdList": ["10.1001/jama.295.13.1549", "16595758"]}, {"Citation": "Pimpley V, Patil S, Srinivasan K, Desai N, Murthy PS. The chemistry of chlorogenic acid from green coffee and its role in attenuation of obesity and diabetes. Preparative Biochem Biotechnol (2020) 50(10):969\u201378. doi: 10.1080/10826068.2020.1786699", "ArticleIdList": ["10.1080/10826068.2020.1786699", "32633686"]}, {"Citation": "Mishra D, Naorem K, Saraswathy KN. Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiometabolic risk factors: A study among Bhil tribal population from two environmental settings. Biochem Genet (2018) 56:295\u2013314. doi: 10.1007/s10528-018-9845-x", "ArticleIdList": ["10.1007/s10528-018-9845-x", "29435690"]}, {"Citation": "Kandpal V, Sachdeva MP, Saraswathy KN. An assessment study of CVD related risk factors in a tribal population of India. BMC Public Health (2016) 16:1\u20138. doi: 10.1186/s12889-016-3106-x", "ArticleIdList": ["10.1186/s12889-016-3106-x", "PMC4880982", "27225632"]}, {"Citation": "Cameron AJ, Zimmet PZ, Dunstan DW, Dalton M, Shaw JE, Welborn TA, et al. . Overweight and obesity in Australia: the 1999\u20132000 Australian diabetes, obesity and lifestyle study (AusDiab). Med J Aust (2003) 178(9):427\u201332. doi: 10.5694/j.1326-5377.2003.tb05283.x", "ArticleIdList": ["10.5694/j.1326-5377.2003.tb05283.x", "12720507"]}, {"Citation": "Ruxton CHS. Nutritional implications of obesity and dieting. Nutr Bull (2011) 36(2):199\u2013211. doi: 10.1111/j.1467-3010.2011.01890.x", "ArticleIdList": ["10.1111/j.1467-3010.2011.01890.x"]}, {"Citation": "Mendez MA, Popkin BM, Buckland G, Schroder H, Amiano P, Barricarte A, et al. . Alternative methods of accounting for underreporting and overreporting when measuring dietary intake-obesity relations. Am J Epidemiol (2011) 173(4):448\u201358. doi: 10.1093/aje/kwq380", "ArticleIdList": ["10.1093/aje/kwq380", "PMC3139974", "21242302"]}, {"Citation": "Paradis AM, Godin G, P\u00e9russe L, Vohl MC. Associations between dietary patterns and obesity phenotypes. Int J Obes (2009) 33(12):1419\u201326. doi: 10.1038/ijo.2009.179", "ArticleIdList": ["10.1038/ijo.2009.179", "19736556"]}, {"Citation": "Abate N. Insulin resistance and obesity: the role of fat distribution pattern. Diabetes Care (1996) 19(3):292\u20134. doi: 10.2337/diacare.19.3.292", "ArticleIdList": ["10.2337/diacare.19.3.292", "8742585"]}, {"Citation": "Kumar M, Kaushik D, Kaur J, Proestos C, Oz F, Oz E, et al. . A critical review on obesity: Herbal approach, bioactive compounds, and their mechanism. Appl Sci (2022) 12(16):8342. doi: 10.3390/app12168342", "ArticleIdList": ["10.3390/app12168342"]}, {"Citation": "Najjar SM, Perdomo G. Hepatic insulin clearance: mechanism and physiology. Physiology (2019) 34(3):198\u2013215. doi: 10.1152/physiol.00048.2018", "ArticleIdList": ["10.1152/physiol.00048.2018", "PMC6734066", "30968756"]}, {"Citation": "Kahn CR. Role of insulin receptors in insulin-resistant states. Metabolism (1980) 29(5):455\u201366. doi: 10.1016/0026-0495(80)90171-7", "ArticleIdList": ["10.1016/0026-0495(80)90171-7", "6990180"]}, {"Citation": "Moller DE, Flier JS. Insulin resistance\u2014mechanisms, syndromes, and implications. New Engl J Med (1991) 325(13):938\u201348. doi:\u00a010.1056/NEJM199109263251307", "ArticleIdList": ["10.1056/NEJM199109263251307", "1881419"]}, {"Citation": "Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (2021) 12:706978. doi: 10.3389/fendo.2021.706978", "ArticleIdList": ["10.3389/fendo.2021.706978", "PMC8450866", "34552557"]}, {"Citation": "Cheng Z, Zhang L, Yang L, Chu H. The critical role of gut microbiota in obesity. Front Endocrinol (2022) 13. doi: 10.3389/fendo.2022.1025706", "ArticleIdList": ["10.3389/fendo.2022.1025706", "PMC9630587", "36339448"]}, {"Citation": "Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol (2014) 28(8):1221\u201338. doi: 10.1210/me.2014-1108", "ArticleIdList": ["10.1210/me.2014-1108", "PMC5414803", "24892638"]}, {"Citation": "Jia Q, Xie Y, Lu C, Zhang A, Lu Y, Lv S, et al. . Endocrine organs of cardiovascular diseases: Gut microbiota. J Cell Mol Med (2019) 23(4):2314\u201323. doi: 10.1111/jcmm.14164", "ArticleIdList": ["10.1111/jcmm.14164", "PMC6433674", "30688023"]}, {"Citation": "Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease. Front Cell infection Microbiol (2021) 86. doi: 10.3389/fcimb.2021.625913", "ArticleIdList": ["10.3389/fcimb.2021.625913", "PMC8010197", "33816335"]}, {"Citation": "Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev (2002) 11(12):1531\u201343.", "ArticleIdList": ["12496040"]}, {"Citation": "Philippe G. Gut microbiota and obesity. Cel Mol Life Sci (2016) 73(1):147\u201362. doi:\u00a010.1007/s00018-015-2061-5", "ArticleIdList": ["10.1007/s00018-015-2061-5", "26459447"]}, {"Citation": "Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J (2017) 474(11):1823\u201336. doi: 10.1042/BCJ20160510", "ArticleIdList": ["10.1042/BCJ20160510", "PMC5433529", "28512250"]}, {"Citation": "Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol (2021) 19(1):55\u201371. doi: 10.1038/s41579-020-0433-9", "ArticleIdList": ["10.1038/s41579-020-0433-9", "32887946"]}, {"Citation": "Li C, Zhou K, Xiao N, Peng M, Tan Z. The effect of qiweibaizhu powder crude polysaccharide on antibiotic-associated diarrhea mice is associated with restoring intestinal mucosal bacteria. Front Nutr (2022) 9. doi: 10.3389/fnut.2022.952647", "ArticleIdList": ["10.3389/fnut.2022.952647", "PMC9305308", "35873450"]}, {"Citation": "Qiao B, Li X, Peng M, Hui H, Tan Z. Alteration of intestinal mucosal microbiota in mice with Chinese dampness-heat syndrom diarrhea by improper diet combined with high temperature and humidity environments. Front Cell Infection Microbiol (2023) 12:1944. doi: 10.3389/fcimb.2022.1096202", "ArticleIdList": ["10.3389/fcimb.2022.1096202", "PMC9845886", "36683693"]}, {"Citation": "Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. . Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J physiology-endocrinol Metab (2006) 290(6):E1253\u201361. doi: 10.1152/ajpendo.00572.2004", "ArticleIdList": ["10.1152/ajpendo.00572.2004", "16531507"]}, {"Citation": "He L, Long C, Liu Y, Guo Y, Xiao N, Tan Z. Effects of Debaryomyces hansenii treatment on intestinal microorganisms in mice with antibiotics-induced diarrhea. 3 Biotech (2017) 7:1\u20137. doi: 10.1007/s13205-017-0953-9", "ArticleIdList": ["10.1007/s13205-017-0953-9", "PMC5612875", "28955644"]}, {"Citation": "Long C, Liu Y, He L, Tan Q, Yu Z, Xiao N, et al. . Bacterial lactase genes diversity in intestinal mucosa of mice with dysbacterial diarrhea induced by antibiotics. 3 Biotech (2018) 8:1\u20139. doi: 10.1007/s13205-018-1191-5", "ArticleIdList": ["10.1007/s13205-018-1191-5", "PMC5847641", "29556430"]}, {"Citation": "Xie G, Tan K, Peng M, Long C, Li D, Tan Z. Bacterial diversity in intestinal mucosa of antibiotic-associated diarrhea mice. 3 Biotech (2019) 9:1\u20138. doi: 10.1007/s13205-019-1967-2", "ArticleIdList": ["10.1007/s13205-019-1967-2", "PMC6842370", "31763122"]}, {"Citation": "Zhou K, Peng M, Deng N, Tan Z, Xiao N. Lactase bacteria in intestinal mucosa are associated with diarrhea caused by high-fat and high-protein diet. BMC Microbiol (2022) 22(1):226. doi: 10.1186/s12866-022-02647-2", "ArticleIdList": ["10.1186/s12866-022-02647-2", "PMC9516839", "36171559"]}, {"Citation": "Liu R, Wakabayashi G, Kim HJ, Choi GH, Yiengpruksawan A, Fong Y, et al. . International consensus statement on robotic hepatectomy surgery in 2018. World J Gastroenterol (2019) 25(12):1432\u2013530. doi: 10.3748/wjg.v25.i12.1432", "ArticleIdList": ["10.3748/wjg.v25.i12.1432", "PMC6441912", "30948907"]}, {"Citation": "Li X, Deng N, Zheng T, Qiao B, Peng M, Xiao N, et al. . Importance of Dendrobium officinale in improving the adverse effects of high-fat diet on mice associated with intestinal contents microbiota. Front Nutr (2022) 9:957334\u20134. doi: 10.3389/fnut.2022.957334", "ArticleIdList": ["10.3389/fnut.2022.957334", "PMC9365999", "35967811"]}, {"Citation": "Wu Y, Zhang C, Shao H, Luo H, Tan Z. Characteristics of intestinal microbiota and enzyme activities in mice fed with lily bulb. 3 Biotech (2021) 11:1\u20138. doi: 10.1007/s13205-020-02597-4", "ArticleIdList": ["10.1007/s13205-020-02597-4", "PMC7778670", "33442516"]}, {"Citation": "Shao H, Zhang C, Wang C, Tan Z. Intestinal mucosal bacterial diversity of antibiotic-associated diarrhea (AAD) mice treated with Debaryomyces hansenii and Qiweibaizhu powder. 3 Biotech (2020) 10:1\u201311. doi: 10.1007/s13205-020-02383-2", "ArticleIdList": ["10.1007/s13205-020-02383-2", "PMC7429618", "32832342"]}, {"Citation": "Yuan Z, Zhang C, Peng X, Shu L, Long C, Tan Z. Intestinal microbiota characteristics of mice treated with Folium senna decoction gavage combined with restraint and tail pinch stress. 3 Biotech (2020) 10:1\u201311. doi: 10.1007/s13205-020-02172-x", "ArticleIdList": ["10.1007/s13205-020-02172-x", "PMC7101465", "32231961"]}, {"Citation": "Zhang C, Shao H, Peng X, Liu T, Tan Z. Microbiotal characteristics colonized in intestinal mucosa of mice with diarrhoea and repeated stress. 3 Biotech (2020) 10:1\u201312. doi: 10.1007/s13205-020-02368-1", "ArticleIdList": ["10.1007/s13205-020-02368-1", "PMC7399726", "32832332"]}, {"Citation": "Long C, Liu Y, He L, Yu R, Li D, Tan Z, et al. . Bacterial lactase genes diversity in intestinal mucosa of dysbacterial diarrhea mice treated with Qiweibaizhu powder. 3 Biotech (2018) 8:1\u20138. doi: 10.1007/s13205-018-1460-3", "ArticleIdList": ["10.1007/s13205-018-1460-3", "PMC6160371", "30280074"]}, {"Citation": "Xie G, Deng N, Zheng T, Peng X, Zhang S, Tan Z. Total glycosides contribute to the anti-diarrheal effects of Qiwei Baizhu Powder via regulating gut microbiota and bile acids. Front Cell Infection Microbiol (2022) 12. doi: 10.3389/fcimb.2022.945263", "ArticleIdList": ["10.3389/fcimb.2022.945263", "PMC9444044", "36072221"]}, {"Citation": "Li X, Zhang C, Tan Z, Yuan J. Network pharmacology-based analysis of gegenqinlian decoction regulating intestinal microbial activity for the treatment of diarrhea. Evidence-Based Complementary Altern Med (2021) 2021:1\u201313. doi: 10.1155/2021/5520015", "ArticleIdList": ["10.1155/2021/5520015", "PMC8331269", "34354757"]}, {"Citation": "Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. . A core gut microbiome in obese and lean twins. Nature (2009) 457:480\u20134. doi: 10.1038/nature07540", "ArticleIdList": ["10.1038/nature07540", "PMC2677729", "19043404"]}, {"Citation": "Wang P, Gao J, Ke W, Wang J, Li D, Liu R, et al. . Resveratrol reduces obesity in high-fat diet-fed mice via modulating the composition and metabolic function of the gut microbiota. Free Radical Biol Med (2020) 156:83\u201398. doi: 10.1016/j.freeradbiomed.2020.04.013", "ArticleIdList": ["10.1016/j.freeradbiomed.2020.04.013", "32305646"]}, {"Citation": "Solano-Aguilar G, Shea-Donohue T, Madden KB, Quinones A, Beshah E, Lakshman S, et al. . Bifidobacterium animalis subspecies lactis modulates the local immune response and glucose uptake in the small intestine of juvenile pigs infected with the parasitic nematode Ascaris suum. Gut Microbes (2018) 9(5):422\u201336. doi: 10.1080/19490976.2018.1460014", "ArticleIdList": ["10.1080/19490976.2018.1460014", "PMC6219643", "30024817"]}, {"Citation": "Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, et al. . Gut microbiota: a new path to treat obesity. Int J Obes Suppl (2019) 9(1):10\u20139. doi: 10.1038/s41367-019-0011-7", "ArticleIdList": ["10.1038/s41367-019-0011-7", "PMC6683132", "31391921"]}, {"Citation": "Wostmann BS, Larkin C, Moriarty A, Bruckner-Kardoss E. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Anim Sci (1983) 33(1):46\u201350.", "ArticleIdList": ["6834773"]}, {"Citation": "Backing F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. . Gutmikrobioten som en milj\u00f8faktor som regulerer fettlagring. Proc Natl Acad Sci USA (2004) 101:15718\u201323. doi: 10.1073/pnas.0407076101", "ArticleIdList": ["10.1073/pnas.0407076101", "PMC524219", "15505215"]}, {"Citation": "O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. . Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomized, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (2018) 392(10148):637\u201349. doi: 10.1016/S0140-6736(18)31773-2", "ArticleIdList": ["10.1016/S0140-6736(18)31773-2", "30122305"]}, {"Citation": "Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. . Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. Jama (2016) 315(22):2424\u201334. doi: 10.1001/jama.2016.7602", "ArticleIdList": ["10.1001/jama.2016.7602", "PMC5617638", "27299618"]}, {"Citation": "Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. . Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. Jama (2016) 315(10):990\u20131004. doi: 10.1001/jama.2016.1558", "ArticleIdList": ["10.1001/jama.2016.1558", "26954408"]}, {"Citation": "Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. . Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med (2016) 375(4):311\u201322. doi: 10.1056/NEJMoa1603827", "ArticleIdList": ["10.1056/NEJMoa1603827", "PMC4985288", "27295427"]}, {"Citation": "Zhang CH, Sheng JQ, Xie WH, Luo XQ, Xue YN, Xu GL, et al. . Mechanism and basis of traditional Chinese medicine against obesity: prevention and treatment strategies. Front Pharmacol (2021) 12:615895. doi: 10.3389/fphar.2021.615895", "ArticleIdList": ["10.3389/fphar.2021.615895", "PMC7982543", "33762940"]}, {"Citation": "Aaseth J, Ellefsen S, Alehagen U, Sundf\u00f8r TM, Alexander J. Diets and drugs for weight loss and health in obesity\u2013An update. Biomed Pharmacother (2021) 140:111789. doi: 10.1016/j.biopha.2021.111789", "ArticleIdList": ["10.1016/j.biopha.2021.111789", "34082399"]}, {"Citation": "Wang L, Yu CC, Li J, Tian Q, Du YJ. Mechanism of action of acupuncture in obesity: a perspective from the hypothalamus. Front Endocrinol (2021) 12:632324. doi: 10.3389/fendo.2021.632324", "ArticleIdList": ["10.3389/fendo.2021.632324", "PMC8050351", "33868169"]}, {"Citation": "de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. . Omentin plasma levels and gene expression are decreased in obesity. Diabetes (2007) 56(6):1655\u201361. doi: 10.2337/db06-1506", "ArticleIdList": ["10.2337/db06-1506", "17329619"]}, {"Citation": "Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology (1985) 89(5):1070\u20137. doi: 10.1016/0016-5085(85)90211-2", "ArticleIdList": ["10.1016/0016-5085(85)90211-2", "3840109"]}, {"Citation": "Fan Q, Xu F, Liang B, Zou X. The anti-obesity effect of traditional Chinese medicine on lipid metabolism. Front Pharmacol (2021) 12:696603. doi: 10.3389/fphar.2021.696603", "ArticleIdList": ["10.3389/fphar.2021.696603", "PMC8255923", "34234682"]}, {"Citation": "Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab (2016) 18(6):558\u201370. doi: 10.1111/dom.12657", "ArticleIdList": ["10.1111/dom.12657", "26936802"]}, {"Citation": "Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. . Richness of human gut microbiome correlates with metabolic markers. Nature (2013) 500(7464):541\u20136. doi:\u00a010.1038/nature12506", "ArticleIdList": ["10.1038/nature12506", "23985870"]}, {"Citation": "Liu G, Liu S, Zuo YZ, Li QY, Wu ZH, Wu N. (1998) 10:4103. 2017. 130."}, {"Citation": "Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. . Gut hormone PYY3-36 physiologically inhibits food intake. Nature (2002) 418(6898):650\u20134. doi: 10.1038/nature00887", "ArticleIdList": ["10.1038/nature00887", "12167864"]}, {"Citation": "Karra E, Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol (2010) 316(2):120\u20138. doi: 10.1016/j.mce.2009.06.010", "ArticleIdList": ["10.1016/j.mce.2009.06.010", "19563862"]}, {"Citation": "Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metabolism (2015) 64(1):146\u201356. doi: 10.1016/j.metabol.2014.07.014", "ArticleIdList": ["10.1016/j.metabol.2014.07.014", "25156686"]}, {"Citation": "Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. . Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. Jama (1999) 282(16):1568\u201375. doi: 10.1001/jama.282.16.1568", "ArticleIdList": ["10.1001/jama.282.16.1568", "10546697"]}, {"Citation": "Pich\u00e9 ME, Tchernof A, Despr\u00e9s JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res (2020) 126(11):1477\u2013500. doi: 10.1161/CIRCRESAHA.120.316101", "ArticleIdList": ["10.1161/CIRCRESAHA.120.316101", "32437302"]}, {"Citation": "Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: current evidence and perspectives. Curr Obes Rep (2019) 8:317\u201332. doi: 10.1007/s13679-019-00352-2", "ArticleIdList": ["10.1007/s13679-019-00352-2", "31175629"]}, {"Citation": "Moszak M, Szuli\u0144ska M, Bogda\u0144ski P. You are what you eat\u2014the relationship between diet, microbiota, and metabolic disorders\u2014a review. Nutrients (2020) 12(4):1096. doi:\u00a010.3390/nu12041096", "ArticleIdList": ["10.3390/nu12041096", "PMC7230850", "32326604"]}, {"Citation": "Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG, Capacci A, et al. . Influence of mediterranean diet on human gut microbiota. Nutrients (2020) 13:7. doi: 10.3390/nu13010007", "ArticleIdList": ["10.3390/nu13010007", "PMC7822000", "33375042"]}, {"Citation": "Qiao B, Li X, Zheng T, Tan Z. Different effects of lard and vegetable blend oil on intestinal microorganisms, enzyme activity and blood routine in mice. J Oleo Sci (2022) 71(2):301\u201310. doi: 10.5650/jos.ess21247", "ArticleIdList": ["10.5650/jos.ess21247", "35034939"]}, {"Citation": "Turnbaugh P, Ley R, Mahowald M, Magrini V, Mardis E, Gordon J. En fedme-assosiert tarmmikrobiom med \u00f8kt kapasitet for energih\u00f8sting. Naturen (2006) 444(7122):1027\u201331. doi:\u00a010.1038/nature05414", "ArticleIdList": ["10.1038/nature05414", "17183312"]}, {"Citation": "Meijnikman AS, Aydin O, Prodan A, Tremaroli V, Herrema H, Levin E, et al. . Distinct differences in gut microbial composition and functional potential from lean to morbidly obese subjects. J Internal Med (2020) 288(6):699\u2013710. doi: 10.1111/joim.13137", "ArticleIdList": ["10.1111/joim.13137", "32633011"]}, {"Citation": "Kobyliak N, Virchenko O, Falalyeyeva T. Pathophysiological role of host microbiota in the development of obesity. Nutr J (2015) 15:1\u201312. doi: 10.1186/s12937-016-0166-9", "ArticleIdList": ["10.1186/s12937-016-0166-9", "PMC4841968", "27105827"]}, {"Citation": "Petersen C, Bell R, Klag KA, Lee SH, Soto R, Ghazaryan A, et al. . T cell\u2013mediated regulation of the microbiota protects against obesity. Science (2019) 365(6451):eaat9351. doi: 10.1126/science.aat9351", "ArticleIdList": ["10.1126/science.aat9351", "PMC7294966", "31346040"]}, {"Citation": "Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. . Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci (2013) 110(22):9066\u201371. doi: 10.1073/pnas.1219451110", "ArticleIdList": ["10.1073/pnas.1219451110", "PMC3670398", "23671105"]}, {"Citation": "Wu D, Wang H, Xie L, Hu F. Cross-talk between gut microbiota and adipose tissues in obesity and related metabolic diseases. Front Endocrinol (2022) 13. doi: 10.3389/fendo.2022.908868", "ArticleIdList": ["10.3389/fendo.2022.908868", "PMC9294175", "35865314"]}, {"Citation": "Koh A, De Vadder F, Kovatcheva-Datchary P, B\u00e4ckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell (2016) 165(6):1332\u201345. doi: 10.1016/j.cell.2016.05.041", "ArticleIdList": ["10.1016/j.cell.2016.05.041", "27259147"]}, {"Citation": "Canfora EE, Meex RC, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol (2019) 15(5):261\u201373. doi: 10.1038/s41574-019-0156-z", "ArticleIdList": ["10.1038/s41574-019-0156-z", "30670819"]}, {"Citation": "Li C, Xiao N, Deng N, Li D, Tan Z, Peng M. Dose of sucrose affects the efficacy of Qiweibaizhu powder on antibiotic-associated diarrhea: association with intestinal mucosal microbiota, short-chain fatty acids, IL-17 and MUC2. Front Microbiol (2023) 14:43. doi: 10.3389/fmicb.2023.1108398", "ArticleIdList": ["10.3389/fmicb.2023.1108398", "PMC9893413", "36744095"]}, {"Citation": "Zhang L, Liu C, Jiang Q, Yin Y. Butyrate in energy metabolism: there is still more to learn. Trends Endocrinol Metab (2021) 32(3):159\u201369. doi: 10.1016/j.tem.2020.12.003", "ArticleIdList": ["10.1016/j.tem.2020.12.003", "33461886"]}, {"Citation": "Cani PD, Hul MV, Lefort C, Depommier C, Rastelli M, Everard A. Microbial regulation of organismal energy homeostasis. Nature metabolism (2019) 1(1):34\u201346. doi: 10.1038/s42255-018-0017-4", "ArticleIdList": ["10.1038/s42255-018-0017-4", "32694818"]}, {"Citation": "Lu Z, Dong TH, Si PR, Shen W, Bi YL, Min M. (2016)."}, {"Citation": "Fogteloo AJ, Pijl H, Fr\u00f6lich M, McCamish M, Meinders AE. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans. Diabetes Nutr Metab (2003) 16(2):109\u201314.", "ArticleIdList": ["12846450"]}, {"Citation": "Ahima RS, Saper CB, Flier JS, Elmquist JK. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol (2000) 21(3):263\u2013307. doi: 10.1006/frne.2000.0197", "ArticleIdList": ["10.1006/frne.2000.0197", "10882542"]}, {"Citation": "Paglialunga S, Schrauwen P, Roy C, Moonen-Kornips E, Lu H, Hesselink MK, et al. . Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J Endocrinol (2007) 194(2):293\u2013304. doi: 10.1677/JOE-07-0205", "ArticleIdList": ["10.1677/JOE-07-0205", "17641279"]}, {"Citation": "Murray I, Havel PJ, Sniderman AD, Cianflone K. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology (2000) 141(3):1041\u20139. doi: 10.1210/endo.141.3.7364", "ArticleIdList": ["10.1210/endo.141.3.7364", "10698180"]}, {"Citation": "Li N, Guo Y, Gong Y, Zhang Y, Fan W, Yao K, et al. . The anti-inflammatory actions and mechanisms of acupuncture from acupoint to target organs via neuro-immune regulation. J Inflammation Res (2021) 14:7191. doi: 10.2147/JIR.S341581", "ArticleIdList": ["10.2147/JIR.S341581", "PMC8710088", "34992414"]}, {"Citation": "Li X, Yin Z, Ling F, Zheng Q, Li X, Qi W, et al. . The application of acupuncture in cardiopathy: A bibliometric analysis based on Web of Science across ten recent years. Front Cardiovasc Med (2022) 9:920491. doi: 10.3389/fcvm.2022.920491", "ArticleIdList": ["10.3389/fcvm.2022.920491", "PMC9485815", "36148057"]}, {"Citation": "Chithanathan K, Somelar K, J\u00fcrgenson M, \u017darkovskaja T, Periyasamy K, Yan L, et al. . Enhanced cognition and neurogenesis in miR-146b deficient mice. Cells (2022) 11(13):2002. doi: 10.3390/cells11132002", "ArticleIdList": ["10.3390/cells11132002", "PMC9265316", "35805086"]}, {"Citation": "Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab (1993) 76(4):819\u201323. doi:\u00a010.1210/jcem.76.4.8473389", "ArticleIdList": ["10.1210/jcem.76.4.8473389", "8473389"]}, {"Citation": "Alvarez-Castro P, Isidro ML, Garcia-Buela J, Leal-Cerro A, Broglio F, Tassone F, et al. . Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients. Clin Endocrinol (2004) 61(2):250\u20135. doi: 10.1111/j.1365-2265.2004.02092.x", "ArticleIdList": ["10.1111/j.1365-2265.2004.02092.x", "15272922"]}, {"Citation": "Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab (2001) 12(3):118\u201322. doi: 10.1016/S1043-2760(00)00362-3", "ArticleIdList": ["10.1016/S1043-2760(00)00362-3", "11306336"]}, {"Citation": "Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes (2001) 50(4):707\u20139. doi: 10.2337/diabetes.50.4.707", "ArticleIdList": ["10.2337/diabetes.50.4.707", "11289032"]}, {"Citation": "Otto B, Cuntz U, Fruehauf EA, Wawarta R, Folwaczny C, Riepl RL, et al. . Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol (2001) 145(5):R5\u20139. doi: 10.1530/EJE-1450669", "ArticleIdList": ["10.1530/EJE-1450669", "11720888"]}, {"Citation": "Tuzcu Z, Orhan C, Sahin N, Juturu V, Sahin K. Cinnamon polyphenol extract inhibits hyperlipidemia and inflammation by modulation of transcription factors in high-fat diet-fed rats. Oxid Med Cell Longevity (2017) 1583098. doi: 10.1155/2017/1583098", "ArticleIdList": ["10.1155/2017/1583098", "PMC5370473", "28396714"]}, {"Citation": "Ukkola O. Ghrelin and insulin metabolism. Eur J Clin Invest (2003) 33(3):183\u20135. doi: 10.1046/j.1365-2362.2003.01112.x", "ArticleIdList": ["10.1046/j.1365-2362.2003.01112.x", "12641533"]}, {"Citation": "Shuto Y, Shibasaki T, Otagiri A, Kuriyama H, Ohata H, Tamura H, et al. . Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest (2002) 109(11):1429\u201336. doi: 10.1172/JCI0213300", "ArticleIdList": ["10.1172/JCI0213300", "PMC150991", "12045256"]}, {"Citation": "Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time-and food-related cues. Am J Physiology-Endocrinol Metab (2004) 287(2):E297\u2013304. doi: 10.1152/ajpendo.00582.2003", "ArticleIdList": ["10.1152/ajpendo.00582.2003", "15039149"]}, {"Citation": "Bjerregaard LG, Jensen BW, \u00c4ngquist L, Osler M, S\u00f8rensen TI, Baker JL. Change in overweight from childhood to early adulthood and risk of type 2 diabetes. New Engl J Med (2018) 378(14):1302\u201312. doi: 10.1056/NEJMoa1713231", "ArticleIdList": ["10.1056/NEJMoa1713231", "29617589"]}, {"Citation": "Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, et al. . Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. New Engl J Med (2016) 374(25):2430\u201340. doi:\u00a010.1056/NEJMoa1503840", "ArticleIdList": ["10.1056/NEJMoa1503840", "27074389"]}, {"Citation": "Belanger MJ, Hill MA, Angelidi AM, Dalamaga M, Sowers JR, Mantzoros CS. Covid-19 and disparities in nutrition and obesity. New Engl J Med (2020) 383(11):e69. doi: 10.1056/NEJMp2021264", "ArticleIdList": ["10.1056/NEJMp2021264", "32668105"]}, {"Citation": "Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. . Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol (2015) 16(1):36\u201346. doi: 10.1016/S1470-2045(14)71123-4", "ArticleIdList": ["10.1016/S1470-2045(14)71123-4", "PMC4314462", "25467404"]}, {"Citation": "Bray MS, Loos RJ, McCaffery JM, Ling C, Franks PW, Weinstock GM. & Conference Working Group. NIH working group report\u2014using genomic information to guide weight management: From universal to precision treatment. Obesity (Silver Spring, Md.) (2016) 24(1):14. doi:\u00a010.1002/oby.21381", "ArticleIdList": ["10.1002/oby.21381", "PMC4689320", "26692578"]}, {"Citation": "Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. . Once-weekly semaglutide in adults with overweight or obesity. New Engl J Med (2021) 384(11):989\u20131002. doi: 10.1056/NEJMoa2032183", "ArticleIdList": ["10.1056/NEJMoa2032183", "33567185"]}, {"Citation": "Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Men's Health (2021) 39(2):208. doi: 10.5534/wjmh.200010", "ArticleIdList": ["10.5534/wjmh.200010", "PMC7994651", "32202085"]}, {"Citation": "Bray GA, Fr\u00fchbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet (2016) 387(10031):1947\u201356. doi: 10.1016/S0140-6736(16)00271-3", "ArticleIdList": ["10.1016/S0140-6736(16)00271-3", "26868660"]}, {"Citation": "Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. New Engl J Med (2017) 376(3):254\u201366. doi: 10.1056/NEJMra1514009", "ArticleIdList": ["10.1056/NEJMra1514009", "28099824"]}, {"Citation": "Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al. . Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab (2016) 23(4):591\u2013601. doi: 10.1016/j.cmet.2016.02.005", "ArticleIdList": ["10.1016/j.cmet.2016.02.005", "PMC4833627", "26916363"]}, {"Citation": "Bl\u00fcher M. Metabolically healthy obesity. Endoc Rev (2020) 41(3):bnaa004. doi:\u00a010.1210/endrev/bnaa004", "ArticleIdList": ["10.1210/endrev/bnaa004", "PMC7098708", "32128581"]}, {"Citation": "Stefan N, H\u00e4ring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol (2018) 6(3):249\u201358. doi: 10.1016/S2213-8587(17)30292-9", "ArticleIdList": ["10.1016/S2213-8587(17)30292-9", "28919065"]}, {"Citation": "Adriaenssens AE, Gribble FM, Reimann F. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system. Peptides (2020) 125:170194. doi: 10.1016/j.peptides.2019.170194", "ArticleIdList": ["10.1016/j.peptides.2019.170194", "31697967"]}, {"Citation": "Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, et al. . Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (2020) 28(6):1050\u201361. doi:\u00a010.1002/oby.22794", "ArticleIdList": ["10.1002/oby.22794", "PMC7318657", "32441473"]}, {"Citation": "Tirosh A, Calay ES, Tuncman G, Claiborn KC, Inouye KE, Eguchi K, et al. . The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Trans Med (2019) 11(489):eaav0120. doi: 10.1126/scitranslmed.aav0120", "ArticleIdList": ["10.1126/scitranslmed.aav0120", "31019023"]}, {"Citation": "Engevik MA, Luck B, Visuthranukul C, Ihekweazu FD, Engevik AC, Shi Z, et al. . Human-derived Bifidobacterium dentium modulates the mammalian serotonergic system and gut\u2013brain axis. Cell Mol Gastroenterol Hepatol (2021) 11(1):221\u201348. doi: 10.1016/j.jcmgh.2020.08.002", "ArticleIdList": ["10.1016/j.jcmgh.2020.08.002", "PMC7683275", "32795610"]}, {"Citation": "Generoso JS, Giridharan VV, Lee J, Macedo D, Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry (2020) 43:293\u2013305. doi: 10.1590/1516-4446-2020-0987", "ArticleIdList": ["10.1590/1516-4446-2020-0987", "PMC8136391", "32667590"]}, {"Citation": "Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. . Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med (2017) 377:1143\u201355. doi: 10.1056/NEJMoa1700459", "ArticleIdList": ["10.1056/NEJMoa1700459", "PMC5737957", "28930514"]}, {"Citation": "Hauner H, Hastreiter L, Werdier D, Chen-Stute A, Scholze J, Bl\u00fcher M. Efficacy and safety of cathine (nor-pseudoephedrine) in the treatment of obesity: a randomized dose-finding study. Obes Facts (2017) 10(4):407\u201319. doi: 10.1159/000478098", "ArticleIdList": ["10.1159/000478098", "PMC5644935", "28873376"]}, {"Citation": "Lucchetta RC, Riveros BS, Pontarolo R, Radominski RB, Otuki MF, Fernandez-Llimos F, et al. . Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics (2017) 72:317\u201324. doi: 10.6061/clinics/2017(05)10", "ArticleIdList": ["10.6061/clinics/2017(05)10", "PMC5439101", "28591345"]}, {"Citation": "M\u00fcller TD, Clemmensen C, Finan B, DiMarchi RD, Tsch\u00f6p MH. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev (2018) 70(4):712\u201346. doi: 10.1124/pr.117.014803", "ArticleIdList": ["10.1124/pr.117.014803", "30087160"]}, {"Citation": "Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. . Semaglutide 2\u00b7 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (2021) 397(10278):971\u201384. doi: 10.1016/S0140-6736(21)00213-0", "ArticleIdList": ["10.1016/S0140-6736(21)00213-0", "33667417"]}, {"Citation": "Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. . Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama (2021) 325(14):1414\u201325. doi: 10.1001/jama.2021.3224", "ArticleIdList": ["10.1001/jama.2021.3224", "PMC7988425", "33755728"]}, {"Citation": "Wilding JP, Calanna S, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. Reply. New Engl J Med (2021) 385(1):e4\u20134. doi: 10.1056/NEJMoa2032183", "ArticleIdList": ["10.1056/NEJMoa2032183", "34192450"]}, {"Citation": "Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota\u2013gut\u2013brain axis in obesity. Lancet Gastroenterol Hepatol (2017) 2(10):747\u201356. doi: 10.1016/S2468-1253(17)30147-4", "ArticleIdList": ["10.1016/S2468-1253(17)30147-4", "28844808"]}, {"Citation": "Oduro-Donkor D, Turner MC, Farnaud S, Renshaw D, Kyrou I, Hanson P, et al. . Modification of fecal microbiota as a mediator of effective weight loss and metabolic benefits following bariatric surgery. Expert Rev Endocrinol Metab (2020) 15(5):363\u201373. doi: 10.1080/17446651.2020.1801412", "ArticleIdList": ["10.1080/17446651.2020.1801412", "32840125"]}, {"Citation": "Cunningham AL, Stephens JW, Harris DA. A review on gut microbiota: a central factor in the pathophysiology of obesity. Lipids Health Dis (2021) 20(1):1\u201313. doi: 10.1186/s12944-021-01491-z", "ArticleIdList": ["10.1186/s12944-021-01491-z", "PMC8262044", "34233682"]}, {"Citation": "Naraoka Y, Yamaguchi T, Hu A, Akimoto K, Kobayashi H. Short chain fatty acids upregulate adipokine production in type 2 diabetes-derived human adipocytes. Acta Endocrinol (Bucharest) (2018) 14(3):287. doi: 10.4183/aeb.2018.287", "ArticleIdList": ["10.4183/aeb.2018.287", "PMC6525780", "31149273"]}, {"Citation": "Kusaczuk M. Tauroursodeoxycholate\u2014bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives. Cells (2019) 8(12):1471. doi:\u00a010.3390/cells8121471", "ArticleIdList": ["10.3390/cells8121471", "PMC6952947", "31757001"]}, {"Citation": "Vettorazzi JF, Kurauti MA, Soares GM, Borck PC, Ferreira SM, Branco RCS, et al. . Bile acid TUDCA improves insulin clearance by increasing the expression of insulin-degrading enzyme in the liver of obese mice. Sci Rep (2017) 7(1):14876. doi: 10.1038/s41598-017-13974-0", "ArticleIdList": ["10.1038/s41598-017-13974-0", "PMC5665899", "29093479"]}, {"Citation": "Zangerolamo L, Vettorazzi JF, Solon C, Bronczek GA, Engel DF, Kurauti MA, et al. . The bile acid TUDCA improves glucose metabolism in streptozotocin-induced Alzheimer's disease mice model. Mol Cell Endocrinol (2021) 521:111116. doi: 10.1016/j.mce.2020.111116", "ArticleIdList": ["10.1016/j.mce.2020.111116", "33321116"]}, {"Citation": "American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care (2021) 44(Suppl 1):S111\u201324. doi:\u00a010.2337/dc21-S009", "ArticleIdList": ["10.2337/dc21-S009", "33298420"]}, {"Citation": "Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs (2019) 79(3):219\u201330. doi: 10.1007/s40265-019-1057-0", "ArticleIdList": ["10.1007/s40265-019-1057-0", "PMC6394798", "30701480"]}, {"Citation": "Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. . Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PloS Genet (2013) 9(10):e1003864. doi: 10.1371/journal.pgen.1003864", "ArticleIdList": ["10.1371/journal.pgen.1003864", "PMC3812053", "24204291"]}, {"Citation": "Bray GA, Kim KK, Wilding JPH, World Obesity Federation . Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev (2017) 18(7):715\u201323. doi:\u00a010.1111/obr.12551", "ArticleIdList": ["10.1111/obr.12551", "28489290"]}, {"Citation": "Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol (2021) 9(7):418. doi: 10.1016/S2213-8587(21)00145-5", "ArticleIdList": ["10.1016/S2213-8587(21)00145-5", "34087168"]}, {"Citation": "Matthias B. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol (2019) 15(5):288\u201398. doi: 10.1038/s41574-019-0176-8", "ArticleIdList": ["10.1038/s41574-019-0176-8", "30814686"]}, {"Citation": "Carlsson LM, Sj\u00f6holm K, Jacobson P, Andersson-Assarsson JC, Svensson PA, Taube M, et al. . Life expectancy after bariatric surgery in the Swedish obese subjects study. New Engl J Med (2020) 383(16):1535\u201343. doi: 10.1056/NEJMoa2002449", "ArticleIdList": ["10.1056/NEJMoa2002449", "PMC7580786", "33053284"]}, {"Citation": "Ugur K, Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol (2019) 2019:2521096. doi: 10.1155/2019/2521096", "ArticleIdList": ["10.1155/2019/2521096", "PMC6458951", "31049060"]}, {"Citation": "Brown LM, Gent L, Davis K, Clegg DJ. Metabolic impact of sex hormones on obesity. Brain Res (2010) 1350:77\u201385. doi: 10.1016/j.brainres.2010.04.056", "ArticleIdList": ["10.1016/j.brainres.2010.04.056", "PMC2924463", "20441773"]}, {"Citation": "Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. . Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer (2012) 118(23):5937\u201346. doi: 10.1002/cncr.27527", "ArticleIdList": ["10.1002/cncr.27527", "PMC3586227", "22926690"]}, {"Citation": "Rothermel J, Lass N, Barth A, Reinehr T. Link between omentin-1, obesity and insulin resistance in children: Findings from a longitudinal intervention study. Pediatr Obes (2020) 15(5):e12605. doi: 10.1111/ijpo.12605", "ArticleIdList": ["10.1111/ijpo.12605", "31840425"]}, {"Citation": "Wroblewski E, Swidnicka-Siergiejko A, Hady HR, Luba M, Konopko M, Kurek K, et al. . Variation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapies. Cytokine (2016) 77:56\u201362. doi: 10.1016/j.cyto.2015.10.013", "ArticleIdList": ["10.1016/j.cyto.2015.10.013", "26539806"]}, {"Citation": "Berstein LM, Ievleva AG, Mukhina MS, Vasiliev DA, Poroshina TE. Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes. Voprosy Onkologii (2016) 63(2):79\u201384.", "ArticleIdList": ["30444337"]}, {"Citation": "Amjad S, Baig M, Zahid N, Tariq S, Rehman R. Association between leptin, obesity, hormonal interplay and male infertility. Andrologia (2019) 51(1):e13147. doi: 10.1111/and.13147", "ArticleIdList": ["10.1111/and.13147", "30255520"]}, {"Citation": "Salas-Huetos A, Maghsoumi-Norouzabad L, James ER, Carrell DT, Aston KI, Jenkins TG, et al. . Male adiposity, sperm parameters and reproductive hormones: An updated systematic review and collaborative meta-analysis. Obes Rev (2021) 22(1):e13082. doi: 10.1111/obr.13082", "ArticleIdList": ["10.1111/obr.13082", "32705766"]}, {"Citation": "Almabhouh FA, Md Mokhtar AH, Malik IA, Aziz NAAA, Durairajanayagam D, Singh HJ. Leptin and reproductive dysfunction in obese men. Andrologia (2020) 52(1):e13433. doi: 10.1111/and.13433", "ArticleIdList": ["10.1111/and.13433", "31773771"]}, {"Citation": "Dornbush S, Aeddula NR. Physiology. In: Leptin. Treasure Island, FL, USA: StatPearls Publishing; (2021).", "ArticleIdList": ["30725723"]}, {"Citation": "Leisegang K, Sengupta P, Agarwal A, Henkel R. Obesity and male infertility: Mechanisms and management. Andrologia (2021) 53(1):e13617. doi: 10.1111/and.13617", "ArticleIdList": ["10.1111/and.13617", "32399992"]}, {"Citation": "Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta (BBA)-Biomembranes (2003) 1609(2):127\u201343. doi: 10.1016/S0005-2736(02)00686-7", "ArticleIdList": ["10.1016/S0005-2736(02)00686-7", "12543373"]}, {"Citation": "Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. . Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem (2007) 282(38):28175\u201388. doi: 10.1074/jbc.M700793200", "ArticleIdList": ["10.1074/jbc.M700793200", "17635925"]}, {"Citation": "Fisette A, Lapointe M, Cianflone K. Obesity-inducing diet promotes acylation stimulating protein resistance. Biochem Biophys Res Commun (2013) 437(3):403\u20137. doi: 10.1016/j.bbrc.2013.06.090", "ArticleIdList": ["10.1016/j.bbrc.2013.06.090", "23831465"]}, {"Citation": "Bays HE, Jones PH, Jacobson TA, Cohen DE, Orringer CE, Kothari S, et al. . Lipids and bariatric procedures part 1 of 2: scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and obesity medicine association: FULL REPORT. J Clin lipidology (2016) 10(1):33\u201357. doi: 10.1016/j.jacl.2015.12.002", "ArticleIdList": ["10.1016/j.jacl.2015.12.002", "26892120"]}, {"Citation": "Ursini F, Abenavoli L. The emerging role of complement C3 as a biomarker of insulin resistance and cardiometabolic diseases: preclinical and clinical evidence. Rev Recent Clin trials (2018) 13(1):61\u20138. doi: 10.2174/1574887112666171128134552", "ArticleIdList": ["10.2174/1574887112666171128134552", "29189176"]}, {"Citation": "Sniderman AD, Cianflone K, Summers L, Fielding B, Frayn K. The acylation-stimulating protein pathway and regulation of postprandial metabolism. Proc Nutr Soc (1997) 56(2):703\u201312. doi: 10.1079/PNS19970070", "ArticleIdList": ["10.1079/PNS19970070", "9264120"]}, {"Citation": "Mishra S, Gupta V, Mishra S, Gupta V, Mahdi AA, Sachan R. An increase level of acylation stimulating protein is correlated with metabolic risk markers in North Indian obese women. Diabetes Metab Syndrome: Clin Res Rev (2017) 11:S797\u2013801. doi: 10.1016/j.dsx.2017.06.001", "ArticleIdList": ["10.1016/j.dsx.2017.06.001", "28610914"]}, {"Citation": "Corvillo F, Akinci B. An overview of lipodystrophy and the role of the complement system. Mol Immunol (2019) 112:223\u201332. doi: 10.1016/j.molimm.2019.05.011", "ArticleIdList": ["10.1016/j.molimm.2019.05.011", "31177059"]}, {"Citation": "Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, et al. . Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin lipidology (2013) 7(4):304\u201383. doi: 10.1016/j.jacl.2013.04.001", "ArticleIdList": ["10.1016/j.jacl.2013.04.001", "23890517"]}, {"Citation": "Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab (2013) 98(10):E1610\u20139. doi: 10.1210/jc.2013-2038", "ArticleIdList": ["10.1210/jc.2013-2038", "23979951"]}, {"Citation": "Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L, et al. . Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol (2010) 109:397\u2013404. doi: 10.1007/s00421-010-1362-5", "ArticleIdList": ["10.1007/s00421-010-1362-5", "PMC2874484", "20131064"]}, {"Citation": "Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. . Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab (2001) 86:5992. doi: 10.1210/jcem.86.12.8111", "ArticleIdList": ["10.1210/jcem.86.12.8111", "11739476"]}, {"Citation": "Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev (2007) 8(1):21\u201334. doi: 10.1111/j.1467-789X.2006.00270.x", "ArticleIdList": ["10.1111/j.1467-789X.2006.00270.x", "17212793"]}, {"Citation": "Wo\u017aniak D, Cichy W, Przys\u0142awski J, Drzyma\u0142a-Czy\u017c S. The role of microbiota and enteroendocrine cells in maintaining homeostasis in the human digestive tract. Adv Med Sci (2021) 66(2):284\u201392. doi: 10.1016/j.advms.2021.05.003", "ArticleIdList": ["10.1016/j.advms.2021.05.003", "34098509"]}, {"Citation": "Wawrzyniak N, Skrypnik K, Suliburska J. Dietary supplements in therapy to support weight reduction in obese patients. Acta Scientiarum Polonorum Technol Alimentaria (2022) 21(1):67\u201380. doi:\u00a010.17306/J.AFS.2022.1010", "ArticleIdList": ["10.17306/J.AFS.2022.1010", "35174689"]}, {"Citation": "Huang M, Cople-Rodrigues CDS, Waitzberg DL, Rocha IMGD, Curioni CC. Changes in the gut microbiota after the use of herbal medicines in overweight and obese individuals: A systematic review. Nutrients (2023) 15(9):2203. doi: 10.3390/nu15092203", "ArticleIdList": ["10.3390/nu15092203", "PMC10181072", "37432344"]}, {"Citation": "\u0141agowska K, Drzyma\u0142a-Czy\u017c S. A low glycemic index, energy-restricted diet but not Lactobacillus rhamnosus supplementation changes fecal short-chain fatty acid and serum lipid concentrations in women with overweight or obesity and polycystic ovary syndrome. Eur Rev Med Pharmacol Sci (2022) 26(3):917\u201326. doi:\u00a010.26355/eurrev_202202_28001", "ArticleIdList": ["10.26355/eurrev_202202_28001", "35179758"]}, {"Citation": "Dixon JB, Le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet (2012) 379(9833):2300\u201311. doi: 10.1016/S0140-6736(12)60401-2", "ArticleIdList": ["10.1016/S0140-6736(12)60401-2", "22683132"]}, {"Citation": "Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. . Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes. N Engl J Med (2017) 376:641\u201351. doi: 10.1056/NEJMoa1600869", "ArticleIdList": ["10.1056/NEJMoa1600869", "PMC5451258", "28199805"]}, {"Citation": "Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Internal Med (2009) 150(2):94\u2013103. doi: 10.7326/0003-4819-150-2-200901200-00007", "ArticleIdList": ["10.7326/0003-4819-150-2-200901200-00007", "19153412"]}, {"Citation": "Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. . Bariatric surgery versus conventional medical therapy for type 2 diabetes. New Engl J Med (2012) 366(17):1577\u201385. doi: 10.1056/NEJMoa1200111", "ArticleIdList": ["10.1056/NEJMoa1200111", "22449317"]}, {"Citation": "Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. . Bariatric surgery versus intensive medical therapy in obese patients with diabetes. New Engl J Med (2012) 366(17):1567\u201376. doi: 10.1056/NEJMoa1200225", "ArticleIdList": ["10.1056/NEJMoa1200225", "PMC3372918", "22449319"]}, {"Citation": "Pournaras DJ, Aasheim ET, S\u00f8vik TT, Andrews R, Mahon D, Welbourn R, et al. . Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. J Br Surg (2012) 99(1):100\u20133. doi:\u00a010.1002/bjs.7704", "ArticleIdList": ["10.1002/bjs.7704", "22021090"]}, {"Citation": "Holst JJ, Madsbad S, Bojsen-M\u00f8ller KN, Svane MS, J\u00f8rgensen NB, Dirksen C, et al. . Mechanisms in bariatric surgery: gut hormones, diabetes resolution, and weight loss. Surg Obes Related Dis (2018) 14(5):708\u201314. doi: 10.1016/j.soard.2018.03.003", "ArticleIdList": ["10.1016/j.soard.2018.03.003", "PMC5974695", "29776493"]}, {"Citation": "Nduma BN, Mofor KA, Tatang JT, Ekhator C, Ambe S, Fonkem E, et al. . Endoscopic gastric sleeve: A review of literature. Cureus (2023) 15(3):e36353. doi: 10.7759/cureus.36353", "ArticleIdList": ["10.7759/cureus.36353", "PMC10112045", "37082499"]}, {"Citation": "Hedjoudje A, Dayyeh BKA, Cheskin LJ, Adam A, Neto MG, Badurdeen D, et al. . Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2020) 18(5):1043\u201353. doi: 10.1016/j.cgh.2019.08.022", "ArticleIdList": ["10.1016/j.cgh.2019.08.022", "31442601"]}, {"Citation": "Jirapinyo P, McCarty TR, Dolan RD, Shah R, Thompson CC. Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2022) 20(3):511\u201324. doi: 10.1016/j.cgh.2021.03.017", "ArticleIdList": ["10.1016/j.cgh.2021.03.017", "33727164"]}, {"Citation": "Sharaiha RZ, Hajifathalian K, Kumar R, Saunders K, Mehta A, Ang B, et al. . Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol (2021) 19(5):1051\u20137. doi: 10.1016/j.cgh.2020.09.055", "ArticleIdList": ["10.1016/j.cgh.2020.09.055", "33011292"]}, {"Citation": "Salomone F, Sharaiha RZ, Bo\u0161koski I. Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: evidence and perspectives. Liver Int (2020) 40(6):1262\u20138. doi: 10.1111/liv.14441", "ArticleIdList": ["10.1111/liv.14441", "32181573"]}, {"Citation": "Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care (2018) 41(5):1106\u201315. doi: 10.2337/dc17-1985", "ArticleIdList": ["10.2337/dc17-1985", "29678867"]}, {"Citation": "Betzel B, Homan J, Aarts EO, Janssen IM, de Boer H, Wahab PJ, et al. . Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg endosc (2017) 31:2881\u201391. doi: 10.1007/s00464-016-5299-6", "ArticleIdList": ["10.1007/s00464-016-5299-6", "27804045"]}, {"Citation": "Zechmeister-Koss I, Hui\u0107 M, Fischer S, European Network for Health Technology Assessment (EUnetHTA) . The duodenal\u2013jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review. Obes Surg (2014) 24:310\u201323. doi: 10.1007/s11695-013-1137-2", "ArticleIdList": ["10.1007/s11695-013-1137-2", "24293185"]}, {"Citation": "Patel SR, Hakim D, Mason J, Hakim N. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes. Surg Obes Related Dis (2013) 9(3):482\u20134. doi: 10.1016/j.soard.2013.01.015", "ArticleIdList": ["10.1016/j.soard.2013.01.015", "23452926"]}, {"Citation": "Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides (2018) 100:61\u20137. doi: 10.1016/j.peptides.2017.12.009", "ArticleIdList": ["10.1016/j.peptides.2017.12.009", "29412833"]}, {"Citation": "Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (2015) 23(6):1119\u201329. doi: 10.1002/oby.21107", "ArticleIdList": ["10.1002/oby.21107", "PMC4692091", "25959380"]}, {"Citation": "Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. . The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res (2022) 182:106320. doi: 10.1016/j.phrs.2022.106320", "ArticleIdList": ["10.1016/j.phrs.2022.106320", "35738455"]}, {"Citation": "Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab (2014) 16(8):673\u201388. doi: 10.1111/dom.12251", "ArticleIdList": ["10.1111/dom.12251", "24373150"]}, {"Citation": "Guo M, Gu J, Teng F, Chen J, Ma X, Chen Q, et al. . The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine (2020) 67:294\u2013304. doi: 10.1007/s12020-019-02175-6", "ArticleIdList": ["10.1007/s12020-019-02175-6", "31900793"]}, {"Citation": "Brown E, Wilding JP, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev (2019) 20(6):816\u201328. doi: 10.1111/obr.12841", "ArticleIdList": ["10.1111/obr.12841", "30972878"]}, {"Citation": "Thomas MC, Coughlan MT, Cooper ME. The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metab (2023) 35(2):253\u201373. doi: 10.1016/j.cmet.2023.01.004", "ArticleIdList": ["10.1016/j.cmet.2023.01.004", "36754019"]}, {"Citation": "Napoli R, Berra C, Catarig AM, Di Loreto C, Donatiello E, Berentzen TL, et al. . Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab (2023) 25(6):1658\u201367. doi: 10.1111/dom.15020", "ArticleIdList": ["10.1111/dom.15020", "36789682"]}, {"Citation": "Foley P, Steinberg D, Levine E, Askew S, Batch BC, Puleo EM, et al. . Track: a randomized controlled trial of a digital health obesity treatment intervention for medically vulnerable primary care patients. Contemp Clin trials (2016) 48:12\u201320. doi: 10.1016/j.cct.2016.03.006", "ArticleIdList": ["10.1016/j.cct.2016.03.006", "PMC4885789", "26995281"]}, {"Citation": "Rhee SY, Kim C, Shin DW, Steinhubl SR. Present and future of digital health in diabetes and metabolic disease. Diabetes Metab J (2020) 44(6):819\u201327. doi: 10.4093/dmj.2020.0088", "ArticleIdList": ["10.4093/dmj.2020.0088", "PMC7801756", "33389956"]}, {"Citation": "Iyengar V, Wolf A, Brown A, Close K. Challenges in diabetes care: can digital health help address them? Clin Diabetes (2016) 34(3):133\u201341. doi: 10.2337/diaclin.34.3.133", "ArticleIdList": ["10.2337/diaclin.34.3.133", "PMC5019009", "27621530"]}, {"Citation": "Soltero EG, Lopez C, Musaad SM, O'Connor TM, Thompson D. Fit24, a digital health intervention to reduce type 2 diabetes risk among Hispanic youth: Protocol for a feasibility pilot study. Contemp Clin Trials (2023) 127:107117. doi: 10.1016/j.cct.2023.107117", "ArticleIdList": ["10.1016/j.cct.2023.107117", "PMC10065958", "36775009"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "5", "Day": "8"}, {"Year": "2023", "Month": "7", "Day": "18"}, {"Year": "2023", "Month": "8", "Day": "22", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "8", "Day": "21", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "8", "Day": "21", "Hour": "4", "Minute": "49"}, {"Year": "2023", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["37600709", "PMC10433171", "10.3389/fendo.2023.1218880"]}}], "PubmedBookArticle": []}